ECSP003594A - HYDROXAMIC ACID DERIVATIVES SUBSTITUTED BY ARILSULFONAMIDO - Google Patents

HYDROXAMIC ACID DERIVATIVES SUBSTITUTED BY ARILSULFONAMIDO

Info

Publication number
ECSP003594A
ECSP003594A EC2000003594A ECSP003594A ECSP003594A EC SP003594 A ECSP003594 A EC SP003594A EC 2000003594 A EC2000003594 A EC 2000003594A EC SP003594 A ECSP003594 A EC SP003594A EC SP003594 A ECSP003594 A EC SP003594A
Authority
EC
Ecuador
Prior art keywords
carbon atoms
substituted
unsubstituted
tri
arilsulfonamido
Prior art date
Application number
EC2000003594A
Other languages
Spanish (es)
Inventor
Werner Breitenstein
Takanori Kanazawa
Kenji Hayakawa
Genji Iwasaki
Tatsuhiko Kasaoka
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP003594A publication Critical patent/ECSP003594A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se describe un derivado de ácido a- aminohidroxámico de la fórmula I (gráfico) en donde R es alquilo de 2 a 7 átomos de carbono, que está mono-, di-, o tri-sustituido por halógeno, nitro, aciloxilo inferior, trifluorometoxilo, ciano, cicloalquilo de 3 a 5 átomos de carbono, o heteroarilo de 3 a 6 átomos de carbono in-sustituido o sustituido que comprende 1 ó 2 heteroátomos seleccionados a partir del grupo que consiste en O,S y N o alquenilo de 3 a 7 átomos de carbono que en cada caso está insustituido o mono-di-, o tri-sustituido por halógeno, nitro, aciloxilo inferior, tri-fluorometoxilo, ciano, cicloalquilo de 3 a 5 átomos de carbono, o heteroarilo de 3 a 6 átomos de cartbono insustituido o sustituido, que comprende 1 ó 2 heteroátomos seleccionados a partir del grupo que consiste en O,S y N y los otros símbolos son como se definen en la reivindicación 1. Estos compuestos son inhibidores de MMP y en particular de MMP2 y se pueden utilizar para el tratamiento de enfermedades dependientes de MMP, en particular condiciones de inflamación artritis reumatoide, osteoartritis, tumores (crecimiento, metástasis, progreso o invasión tumoral) y desordenes pulmonares (por ejemplo enfisema, COPD).An a-aminohydroxamic acid derivative of the formula I (graph) is described wherein R is alkyl of 2 to 7 carbon atoms, which is mono-, di-, or tri-substituted by halogen, nitro, lower acyloxy, trifluoromethoxy , cyano, cycloalkyl of 3 to 5 carbon atoms, or heteroaryl of 3 to 6 unsubstituted or substituted carbon atoms comprising 1 or 2 heteroatoms selected from the group consisting of O, S and N or alkenyl of 3 to 7 carbon atoms which in each case are unsubstituted or mono-di-, or tri-substituted by halogen, nitro, lower acyloxy, tri-fluoromethoxy, cyano, cycloalkyl of 3 to 5 carbon atoms, or heteroaryl of 3 to 6 atoms of unsubstituted or substituted carbon, comprising 1 or 2 heteroatoms selected from the group consisting of O, S and N and the other symbols are as defined in claim 1. These compounds are MMP inhibitors and in particular MMP2 and can be used to treat enf MMP-dependent diseases, in particular conditions of rheumatoid arthritis inflammation, osteoarthritis, tumors (growth, metastasis, progress or tumor invasion) and pulmonary disorders (eg emphysema, COPD).

EC2000003594A 1999-08-09 2000-07-31 HYDROXAMIC ACID DERIVATIVES SUBSTITUTED BY ARILSULFONAMIDO ECSP003594A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9918684.3A GB9918684D0 (en) 1999-08-09 1999-08-09 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP003594A true ECSP003594A (en) 2002-02-25

Family

ID=10858792

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2000003594A ECSP003594A (en) 1999-08-09 2000-07-31 HYDROXAMIC ACID DERIVATIVES SUBSTITUTED BY ARILSULFONAMIDO

Country Status (29)

Country Link
US (2) US7138432B1 (en)
EP (2) EP1202961B1 (en)
JP (2) JP4338925B2 (en)
KR (1) KR20020022807A (en)
CN (1) CN1215055C (en)
AR (1) AR035556A1 (en)
AT (1) ATE455754T1 (en)
AU (1) AU766328B2 (en)
BR (1) BR0013074A (en)
CA (1) CA2378310A1 (en)
CO (1) CO5251438A1 (en)
CZ (1) CZ2002463A3 (en)
DE (1) DE60043730D1 (en)
EC (1) ECSP003594A (en)
ES (1) ES2338748T3 (en)
GB (1) GB9918684D0 (en)
HK (1) HK1048981B (en)
HU (1) HUP0202934A3 (en)
IL (1) IL147216A0 (en)
MX (1) MXPA02001418A (en)
NO (1) NO20020596L (en)
PE (1) PE20010403A1 (en)
PL (1) PL353188A1 (en)
PT (1) PT1202961E (en)
RU (1) RU2265592C2 (en)
SK (1) SK1882002A3 (en)
TR (1) TR200200145T2 (en)
WO (1) WO2001010827A1 (en)
ZA (1) ZA200200996B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0103303D0 (en) * 2001-02-09 2001-03-28 Novartis Ag Organic compounds
CA2357110A1 (en) * 2001-04-11 2002-10-11 American Cyanamid Company Method for the treatment of polycystic kidney disease
US7488754B2 (en) 2002-04-05 2009-02-10 Wyeth Method for the treatment of polycystic kidney disease
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
US8030356B2 (en) 2006-03-17 2011-10-04 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
KR20080104347A (en) * 2006-03-29 2008-12-02 노파르티스 아게 Selective Hydroxamate-Based MPM Inhibitor
BRPI0713463A2 (en) * 2006-06-22 2012-01-24 Atrazeneca Ab E Astex Therapeutics Ltd compound, pharmaceutical formulation, use of a compound, and methods for inhibiting bace activity and for treating or preventing a condition
CN104119310B (en) 2007-09-26 2017-04-12 约翰斯霍普金斯大学 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors, and medical compositions containing same
ITTO20090648A1 (en) * 2009-08-19 2011-02-20 Istituto Naz Per La Ricerca Sul Cancro INHIBITORS OF ADAM17 ACTS TO MODULATE THE RELEASE OF ALCAM (CD166) SOLUBLE IN TUMOR CELLS AND THEIR USE IN THE THERAPEUTIC TREATMENT OF THE EPITHELIAL OVARIC CARCINOMA (EOC)
CN103619805A (en) * 2011-05-27 2014-03-05 国立大学法人德岛大学 Benzylamine derivative
US9023318B2 (en) 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
JP6177246B2 (en) 2011-10-17 2017-08-09 ザ・ジョンズ・ホプキンス・ユニバーシティ Meldrum acid, barbituric acid, and pyrazolone derivatives as HNO donors substituted with hydroxylamine
SG10201802862WA (en) 2013-01-18 2018-05-30 Cardioxyl Pharmaceuticals Inc Pharmaceutical compositions comprising nitroxyl donors
ES2734060T3 (en) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Nitroxyl donors of N-hydroxymethanesulfonamide
EP3148972B1 (en) 2014-05-27 2019-08-21 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
CA3082972C (en) * 2017-11-27 2022-10-11 Council Of Scientific & Industrial Research Indole (sulfomyl) n-hydroxy benzamide derivatives as selective hdac inhibitors
CN114450294B (en) * 2019-11-08 2024-11-26 大正制药株式会社 Peptides with MMP2 inhibitory activity

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2513826A (en) 1946-12-05 1950-07-04 Gen Aniline & Film Corp Aromatic sulfonhydrazides
US4772733A (en) * 1986-07-17 1988-09-20 Hercules Incorporated Epoxy-azides
US4959501A (en) * 1987-09-04 1990-09-25 Ciba-Geigy Corporation Process for the preparation of 2-(2-chloroethoxy)-benzenesulfonamide
FR2665441B1 (en) * 1990-07-31 1992-12-04 Sanofi Sa N-SULFONYL INDOLINE DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
FR2682498A1 (en) * 1991-10-15 1993-04-16 Kodak Pathe Colouring agents containing thioether macrocycles
FR2686878B1 (en) * 1992-01-30 1995-06-30 Sanofi Elf DERIVATIVES OF N-SULFONYL OXO-2 INDOLE, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5646167A (en) * 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9503749D0 (en) * 1995-02-24 1995-04-12 British Biotech Pharm Synthesis of hydroxamic acid derivatives
TW453995B (en) * 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
BR9707010B1 (en) 1996-01-23 2009-05-05 compounds, pharmaceutical composition and compositions for inhibiting type iv metalloproteinase and collagenase.
CA2242416C (en) 1996-01-23 2006-03-21 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
CN1077885C (en) 1996-05-17 2002-01-16 沃尼尔·朗伯公司 Biphenylsulfonamide matrix metalloproteinase inhibitors
WO1997045402A1 (en) 1996-05-24 1997-12-04 Ono Pharmaceutical Co., Ltd. Phenylsulfonamide derivatives
AU5426398A (en) 1996-10-28 1998-05-22 Versicor Inc Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
KR20000057444A (en) 1996-12-09 2000-09-15 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Method for treating and preventing heart failure and ventricular dilatation
NZ336840A (en) * 1997-02-03 2001-01-26 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases
US5985900A (en) * 1997-04-01 1999-11-16 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
GB9708133D0 (en) 1997-04-22 1997-06-11 British Biotech Pharm Novel use of matrix metalloproteinase inhibitors
PT877019E (en) 1997-05-09 2002-05-31 Hoechst Ag SUBSTITUTED DIAMINOCARBOXYLIC ACIDS
DE19719621A1 (en) 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarboxylic acids
CA2298617A1 (en) * 1997-07-31 1999-02-11 Yetunde Olabisi Taiwo Acyclic metalloprotease inhibitors
IL127496A0 (en) 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
JP4750272B2 (en) 1998-02-04 2011-08-17 ノバルティス アーゲー Sulfonylamino derivatives that inhibit matrix-degrading metalloproteinases
JPH11236369A (en) 1998-02-23 1999-08-31 Kotobuki Seiyaku Kk Sulfonamide derivative, method for producing the same, and pharmaceutical composition containing the same
PA8469301A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc PROCEDURES FOR THE PREPARATION OF HYDROXAMIC ACIDS.
AR035313A1 (en) 1999-01-27 2004-05-12 Wyeth Corp ACETILENIC TACE INHIBITORS OF HYDROXAMIC ACID OF SULFONAMIDE BASED ON ALFA-AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES.
AR035311A1 (en) * 1999-01-27 2004-05-12 Wyeth Corp HYDROXAMIC ACID DERIVATIVES CONTAINING ALQUINYL, AS INHIBITORS OF THE METALLOPROTEINAS OF MATRIX AND THE TACE, PHARMACEUTICAL COMPOSITION AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
KR20020022807A (en) 2002-03-27
MXPA02001418A (en) 2002-07-30
HK1048981A1 (en) 2003-04-25
CA2378310A1 (en) 2001-02-15
EP2085379A1 (en) 2009-08-05
NO20020596L (en) 2002-04-08
CO5251438A1 (en) 2003-02-28
BR0013074A (en) 2002-08-13
ES2338748T3 (en) 2010-05-12
HUP0202934A3 (en) 2005-06-28
HK1048981B (en) 2006-03-03
CN1215055C (en) 2005-08-17
CN1368958A (en) 2002-09-11
AU6440300A (en) 2001-03-05
PL353188A1 (en) 2003-11-03
HUP0202934A2 (en) 2003-01-28
AU766328B2 (en) 2003-10-16
US7138432B1 (en) 2006-11-21
RU2265592C2 (en) 2005-12-10
JP2009235071A (en) 2009-10-15
SK1882002A3 (en) 2002-07-02
EP1202961A1 (en) 2002-05-08
GB9918684D0 (en) 1999-10-13
US8034810B2 (en) 2011-10-11
PE20010403A1 (en) 2001-04-11
JP4338925B2 (en) 2009-10-07
IL147216A0 (en) 2002-08-14
ZA200200996B (en) 2003-08-27
NO20020596D0 (en) 2002-02-06
TR200200145T2 (en) 2002-06-21
WO2001010827A1 (en) 2001-02-15
AR035556A1 (en) 2004-06-16
PT1202961E (en) 2010-03-16
ATE455754T1 (en) 2010-02-15
CZ2002463A3 (en) 2002-05-15
DE60043730D1 (en) 2010-03-11
JP2003506434A (en) 2003-02-18
EP1202961B1 (en) 2010-01-20
US20080275127A1 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
ECSP003594A (en) HYDROXAMIC ACID DERIVATIVES SUBSTITUTED BY ARILSULFONAMIDO
EA200400498A1 (en) Phenylpyrazine derivatives as inhibitors of serotonin reuptake
AR060873A1 (en) BICYCLE DERIVATIVES AS CETP INHIBITORS
CR7038A (en) AMIDA DERIVATIVES OF TIAZOLILICO, OXAZOLILICO, PIRROLILICO AND IMIDIAZOLILICO ACIDS USED AS INHIBITORS OF THE ISOZIMAS PDE4
PT1297851E (en) INHIBITION OF HISTONE-DESACETILASE AS TREATMENT FOR CARDIAC HYPERTROPHY
PE20070855A1 (en) DERIVATIVES OF 4-AMINO-PYRROLOTRIAZINE SUBSTITUTE AS KINASE INHIBITORS
BRPI0414716A (en) 1,4-disubstituted isoquinylone derivatives as rafase kinase inhibitors useful for the treatment of proliferative diseases
PE20060644A1 (en) PROCEDURE FOR THE PREPARATION OF DIHYDROPTERIDINONES
CY1116343T1 (en) FOLKA, COMPOSITIONS AND USES OF THESE
CO6321144A2 (en) COMPOSITIONS OF PERACIDO AND 2-HYDROXI ORGANIC ACID AND METHODS TO TREAT AGRICULTURAL PRODUCTS
EA201390405A1 (en) INHIBITORS OF MATRIC METAL PROTEINASE
EA200000804A1 (en) META-AZACLIC COMPOUNDS OF AMINOBENZOIC ACID AND THEIR DERIVATIVES, WHICH ARE INTEGRINE INHIBITORS
AR063415A1 (en) ERLOTINIB CHLORHYDRATE HYDRATES FOR CANCER TREATMENT
EA202190902A1 (en) FATTY ACID SYNTHASE INHIBITION (FASN)
CO5040010A1 (en) ISOTIAZOLCARBOXILIC ACID DERIVATIVES
MX9605366A (en) BICYCLE AMIDINE DERIVATIVES AS INHIBITORS OF NITRIC OXIDE SYNTHETIC.
EA200701470A1 (en) METHODS OF OBTAINING DERIVATIVES OF 4- (FENOXY-5-METHYLPYRIMIDIN-4-ILOXI) PIPERIDIN-1-CARBIC ACID AND RELATED COMPOUNDS
AR043505A1 (en) PREPARATION OF BETA-CETOAMIDS AND REACTION INTERMEDIARIES
BR0314128A (en) Process for the preparation of useful intermediates for the synthesis of tubulin inhibitors
US9102602B2 (en) Method for producing isothiocyanate compound
EA200400102A1 (en) NEW HETEROARRYNE DERIVATIVES, THEIR RECEIVING AND USE
ES2630392T3 (en) Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide
CA2986943A1 (en) Process for the preparation of enzalutamide
BR112015029822A2 (en) methods for synthesizing ingenol and compounds, and, compound
DK1745010T3 (en) Substituted cyclohexyl-1,4-diamine derivatives